Skip to main content
. 2021 Feb 20;12(9):1577–1585. doi: 10.1111/jdi.13502

Figure 3.

Figure 3

Changes in the mean estimated glomerular filtration rate (eGFR) slope before and after sodium–glucose cotransporter 2 inhibitors (SGLT2is) administration, in each stage of annual eGFR decline before SGLT2i administration. (a) The mean eGFR over time course before and after administration of SGLT2is in patient groups with the annual eGFR decline of >3 mL/min/1.73 m2, 1–3 mL/min/1.73 m2 and <1 mL/min/1.73 m2 before SGLT2is administration, respectively. The number of patients who had eGFR data during the observational periods is shown in the lower panel of the graph of mean eGFR. Differences in changes in the mean eGFR slope before and after SGLT2is administration at each level of the eGFR slope before SGLT2is administration for patient groups with eGFR decline of (b) >3 mL/min/1.73 m2, (c) 1–3 mL/min/1.73 m2 and (d) <1 mL/min/1.73 m2. Data are shown as the mean ± standard error (SE). ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; −24 to 0 months (M) vs 0–24 M.